Product Information
TELMISARTAN 40 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1503 per EA under NDC 65862086830. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application on Sep 3, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862086830
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TELMISARTANApproval Type
Generic (ANDA)
FDA Application
ANDA206511FDA Approved
9/3/2015
TE Code
AB
On Market Since
9/3/2015
Pharmacological Classes
Price Statistics
The NADAC for TELMISARTAN 40 MG TABLET has been published 237 times since Mar 23, 2022, and over the history we have for it it has declined 58.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1503 per EA |
|---|---|
| All-time high | $0.3586 (Apr 13, 2022) |
| All-time low | $0.1274 (Nov 20, 2024) |
| 52-week high | $0.1808 |
| 52-week low | $0.1503 |
| Median price | $0.2135 |
| Average price | $0.2202 |
| Largest weekly change | -33.0% (Nov 20, 2024) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Telmisartan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TELMISARTAN 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TELMISARTAN 40 MG TABLET, manufactured by Aurobindo Pharma Limited, is $0.1503 per EA (NDC 65862086830), effective Sep 30, 2026.
How has the price of TELMISARTAN 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for TELMISARTAN 40 MG TABLET has declined 58.1%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for TELMISARTAN 40 MG TABLET?
Since Mar 23, 2022, the NADAC for TELMISARTAN 40 MG TABLET has ranged from a low of $0.1274 (Nov 20, 2024) to a high of $0.3586 (Apr 13, 2022), with a median of $0.2135 per EA.
Are there cheaper alternatives to TELMISARTAN 40 MG TABLET?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TELMISARTAN 40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TELMISARTAN 40 MG TABLET?
TELMISARTAN 40 MG TABLET (NDC 65862086830) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.